{
 "name": "德英",
 "slug": "tw-4911",
 "aliases": [
  "德英生物科技股份有限公司",
  "G&E",
  "4911"
 ],
 "ticker": "4911",
 "industry": "生技醫療業",
 "website": "www.geherbs.com.tw",
 "summary": "德英（4911）是上櫃的生技醫療類股公司，2002 年成立，2011 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "德英生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "G&E",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2011-03-21",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2002-08-06",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "郭國華",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "郭國華",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 688171330,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "www.geherbs.com.tw",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 11440,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔來源為二手連結，回查官方115年09月營收逐欄一致；僅修source並加註，claim/value/unit/as_of均保留。出表日1151017。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -56.02,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔來源為二手連結，回查官方115年09月營收逐欄一致；僅修source並加註，claim/value/unit/as_of均保留。出表日1151017。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -57.93,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔來源為二手連結，回查官方115年09月營收逐欄一致；僅修source並加註，claim/value/unit/as_of均保留。出表日1151017。"
  },
  {
   "claim": "產品許可：利保肝膠囊70毫克（Hepanamin；silymarin）",
   "value": "TFDA 衛署藥製字第031910號｜台灣｜1989-11-04",
   "unit": "",
   "as_of": "2024-05-31",
   "source": "https://data.fda.gov.tw/opendata/exportDataList.do?method=ExportData&InfoId=36&logType=2",
   "note": "36_2.csv以許可證字號定位；as_of是異動日期，value為發證日期。申請商為八馬國際事業有限公司，德英為製造商；不把製造商寫成藥證持有人。"
  },
  {
   "claim": "管線：SR-T100凝膠（尋常疣）",
   "value": "尋常疣｜臨床二期；登錄暫停｜地區未揭露",
   "unit": "",
   "as_of": "2023-09-14",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT01796795",
   "note": "NCT01796795；歷史登錄截至Last Update Posted，不據此宣稱2026仍招募或已上市；核對日2026-10-22。 此登錄版本未列試驗地點，不以贊助商國別推定試驗地區。"
  },
  {
   "claim": "管線：SR-T100凝膠（外生殖器疣）",
   "value": "外生殖器疣/尖銳濕疣｜臨床二期已完成｜台灣",
   "unit": "",
   "as_of": "2020-02-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT01796821",
   "note": "NCT01796821；歷史登錄截至Last Update Posted，不據此宣稱2026仍招募或已上市；核對日2026-10-22。"
  },
  {
   "claim": "管線：SR-T100凝膠（日光角化症）",
   "value": "日光角化症｜臨床三期已完成｜台灣",
   "unit": "",
   "as_of": "2016-02-19",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT01493921",
   "note": "NCT01493921；歷史登錄截至Last Update Posted，不據此宣稱2026仍招募或已上市；核對日2026-10-22。"
  },
  {
   "claim": "管線：SR-T100（注射劑）",
   "value": "癌症惡性腹水｜已向TFDA申請臨床一期IND，待審查核准｜台灣",
   "unit": "",
   "as_of": "2026-07-01",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "公司4911；年度115；發言日期2026-07-01 14:37:31；序號1；主旨：公告本公司研發之新藥SR-T100注射劑（治療癌症惡性腹水）已正式向TFDA提出第一期人體臨床試驗（IND）申請。尚未宣稱IND核准/臨床啟動；公告未給具體後續日期。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-4911.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}